Pharming Group (NASDAQ:PHAR) Upgraded at Weiss Ratings

Weiss Ratings upgraded shares of Pharming Group (NASDAQ:PHAR) from a sell (d+) rating to a hold (c-) rating in a report issued on Saturday morning,Weiss Ratings reports.

Separately, Zacks Research downgraded shares of Pharming Group from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 30th. Three equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $30.00.

Pharming Group Stock Performance

PHAR stock opened at $13.33 on Friday. The company has a quick ratio of 2.07, a current ratio of 2.79 and a debt-to-equity ratio of 0.38. The business’s fifty day simple moving average is $14.29 and its two-hundred day simple moving average is $11.68. Pharming Group has a twelve month low of $7.31 and a twelve month high of $17.08. The firm has a market cap of $913.24 million, a price-to-earnings ratio of -102.54 and a beta of 0.04.

Pharming Group (NASDAQ:PHAR) last released its earnings results on Thursday, July 31st. The company reported $0.06 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.16. The business had revenue of $93.20 million for the quarter, compared to analyst estimates of $70.36 million. Pharming Group had a negative return on equity of 3.31% and a negative net margin of 2.19%. Pharming Group has set its FY 2025 guidance at EPS. Analysts predict that Pharming Group will post -0.2 earnings per share for the current year.

Institutional Investors Weigh In On Pharming Group

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC lifted its stake in Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) by 8.6% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 52,147 shares of the company’s stock after buying an additional 4,150 shares during the quarter. Silverberg Bernstein Capital Management LLC owned approximately 0.08% of Pharming Group worth $557,000 as of its most recent SEC filing. Institutional investors and hedge funds own 0.03% of the company’s stock.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.